Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity

Anti-Cancer Drugs

Volumn 25, Issue 2, 2014, Pages 204-211

  Zhang, Xiaohua ^a   Fang, Xianying ^b   Gao, Zhenzhen ^a   Chen, Wei ^b   Tao, Feifei ^b   Cai, Peifen ^a   Yuan, Huaqin ^a   Shu, Yongqian ^a   Xu, Qiang ^b   Sun, Yang ^b   Gu, Yanhong ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

antitumor immunity; axitinib; metastasis; myeloid derived suppressor cells; vascular endothelial growth factor

Indexed keywords

ARGINASE 1; AXITINIB; CD31 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LIFESPAN; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891863408     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000033     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300
2. Kasper B, D'Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: A new beginning? Crit Rev Oncol Hematol 2007; 62:16-22
3. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer 2012; 12:349-361
4. Recchia F, Candeloro G, Necozione S, Fumagalli L, Bratta M, Rea S. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma. Anticancer Drugs 2008; 19:201-207
5. Ugurel S. Chemotherapy in metastatic melanoma - still useful or out of date? Onkologie 2011; 34:159-160
6. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009; 9:587-595
7. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674
8. Park EJ, Choi KS, Yoo YH, Kwon TK. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation. Anticancer Drugs 2013; 24:260-269
9. Cardenas MG, Blank VC, Marder MN, Roguin LP. 20-Nitroflavone induces apoptosis and modulates mitogen-activated protein kinase pathways in human leukaemia cells. Anticancer Drugs 2012; 23:815-826
10. Rapisarda A, Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 2012; 114:237-267
11. Zhang C, Tan C, Ding H, Xin T, Jiang Y. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials. Curr Pharm Des 2012; 18:2921-2935
12. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28:367-388
13. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2Ddeficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28:571-580
14. Schafer M, Werner S. Cancer as an overhealing wound: An old hypothesis revisited. Nat Rev Mol Cell Biol 2008; 9:628-638
15. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-271
16. Radoja S, Rao TD, Hillman D, Frey AB. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. J Immunol 2000; 164:2619-2628
17. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8:618-631
18. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007; 67:10019-10026
19. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, et al. IL-4- induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003; 170:270-278
20. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002; 168:689-695
21. Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, OsenW, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 2011; 108:17111-17116
22. Zhao X, Rong L, Li X, Liu X, Deng J, Wu H, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 2012; 122:4094-4104
23. Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 2013; 38:541-554
24. Sihto H, Bohling T, Kavola H, Koljonen V, Salmi M, Jalkanen S, et al. Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: A populationbased study. Clin Cancer Res 2012; 18:2872-2881
25. Facchini G, Perri F, Caraglia M, Pisano C, Striano S, Marra L, et al. New treatment approaches in renal cell carcinoma. Anticancer Drugs 2009; 20:893-900
26. Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 2011; 17:7462-7469
27. Bose A, Lowe DB, Rao A, Storkus WJ. Combined vaccine + axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 2012; 22:236-243
28. Fang XY, Chen W, Fan JT, Song R,Wang L, Gu YH, et al. Plant cyclopeptide RA-V kills human breast cancer cells by inducing mitochondria-mediated apoptosis through blocking PDK1-AKT interaction. Toxicol Appl Pharmacol 2013; 267:95-103
29. Guo WJ, Zhang YM, Zhang L, Huang B, Tao FF, Chen W, et al. Novel monofunctional platinum (II) complex Mono-Pt induces apoptosisindependent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin. Autophagy 2013; 9:996-1008
30. Sondak VK, Smalley KSM, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov 2011; 10:411-412
31. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME,Wickman GR, Amundson K, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008; 14:7272-7283
32. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12:895-904
33. Van Kempen LC, Coussens LM. MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002; 2:251-252
34. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-444
35. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al. Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30:83-95
36. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22:238-244
37. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-174